^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Nasopharyngeal Carcinoma |
| Drug: | Loqtorzi (toripalimab-tpzi) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
10/27/2023
Excerpt:
LOQTORZI is a programmed death receptor-1 (PD-1)- blocking antibody indicated...in combination with cisplatin and gemcitabine, for first-line treatment of adults with metastatic or with recurrent locally advanced nasopharyngeal carcinoma
Secondary therapy:
cisplatin + gemcitabine
Source:
Title:
NMPA Approves Toripalimab in Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma after Failure of at Least Two Lines of Prior Systemic Therapy
Published date:
02/21/2021
Excerpt:
Junshi Biosciences…announced today that the National Medical Products Administration (NMPA) of China has granted a conditional approval to toripalimab for the treatment of patients with recurrent or metastatic nasopharyngeal carcinoma (NPC) after failure of at least two lines of prior systemic therapy.
Source:
Published date:
12/08/2023
Excerpt:
Cancer of the Nasopharynx: Preferred Regimens...Cisplatin/gemcitabine + toripalimab-tpzi…Subsequent-Line...Toripalimab-tpzi...
Secondary therapy:
cisplatin + gemcitabine
Source:
Title:
Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers: ASCO Guideline
Published date:
12/15/2022
Excerpt:
Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers....Recommendation 4.1….Toripalimab, camrelizumab, or tislelizumab, with gemcitabine and cisplatin, should be offered as first-line treatment for patients with recurrent or metastatic nasopharyngeal cancer
Secondary therapy:
cisplatin + gemcitabine
DOI:
10.1200/JCO.22.02328
Source:
Title:
Coherus Announces Positive Final Overall Survival Results of JUPITER-02 Phase 3 Trial Evaluating Toripalimab in Nasopharyngeal Carcinoma
Published date:
06/05/2023
Excerpt:
Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) announced the final overall survival (OS) results of the JUPITER-02 study...The final analysis of the JUPITER-02 clinical trial (NCT03581786) demonstrated a statistically significant and clinically meaningful improvement in OS for NPC patients who were treated with toripalimab in combination with gemcitabine and cisplatin chemotherapy, versus chemotherapy treatment alone.
Secondary therapy:
cisplatin + gemcitabine
Trial ID:
Source:
Title:
Coherus and Junshi Biosciences Announce FDA Acceptance of BLA Filing for Toripalimab for Treatment of Nasopharyngeal Carcinoma
Published date:
11/01/2021
Excerpt:
Coherus BioSciences...The FDA has granted Priority Review Designation for the toripalimab BLA and set a Prescription Drug User Fee Act ("PDUFA") action date for April 2022.
Title:
Junshi Biosciences and Coherus Announce U.S. FDA BTD Granted for Toripalimab for 1st Line NPC
Published date:
08/12/2021
Excerpt:
Shanghai Junshi Biosciences Co., Ltd...today announced that the United States Food and Drug Administration (“FDA”) has recently granted Breakthrough Therapy Designation (“BTD”) for toripalimab in combination with chemotherapy (gemcitabine and cisplatin) for the 1st line treatment of recurrent or metastatic nasopharyngeal carcinoma (“NPC”).
Secondary therapy:
cisplatin + gemcitabine
Source:
Title:
Junshi Biosciences Receives FDA Breakthrough Therapy Designation for Toripalimab for the Treatment of Nasopharyngeal Carcinoma
Published date:
09/10/2020
Excerpt:
Junshi Biosciences...announced today that the US Food and Drug Administration (FDA) has recently granted Breakthrough Therapy designation (BTD) to Toripalimab for the treatment of nasopharyngeal carcinoma.
